Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Ekso Bionics Holdings (EKSO) Research & Development (2016 - 2026)

Ekso Bionics Holdings has reported Research & Development over the past 13 years, most recently at $642000.0 for Q4 2025.

  • On a quarterly basis, Research & Development fell 24.02% to $642000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $3.0 million, a 21.73% decrease, with the full-year FY2025 number at $3.0 million, down 21.76% from a year prior.
  • Research & Development reached $642000.0 in Q4 2025 per EKSO's latest filing, up from $550000.0 in the prior quarter.
  • The five-year high for Research & Development was $1.4 million in Q2 2023, with the low at $550000.0 in Q3 2025.
  • The 5-year median for Research & Development is $880000.0 (2022), against an average of $905300.0.
  • Peak YoY movement for Research & Development: soared 60.14% in 2023, then crashed 35.64% in 2024.
  • Tracing EKSO's Research & Development over 5 years: stood at $619000.0 in 2021, then skyrocketed by 52.83% to $946000.0 in 2022, then surged by 38.79% to $1.3 million in 2023, then crashed by 35.64% to $845000.0 in 2024, then decreased by 24.02% to $642000.0 in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $642000.0, $550000.0, and $852000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.